Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1969 1
1970 2
1971 9
1972 3
1973 3
1979 1
1980 2
1981 1
1982 1
1983 1
1984 2
1985 2
1986 5
1987 5
1988 3
1989 6
1990 16
1991 11
1992 8
1993 17
1994 9
1995 18
1996 20
1997 33
1998 36
1999 47
2000 62
2001 71
2002 74
2003 93
2004 129
2005 168
2006 207
2007 239
2008 257
2009 301
2010 344
2011 394
2012 501
2013 560
2014 584
2015 536
2016 600
2017 603
2018 580
2019 587
2020 614
2021 668
2022 583
2023 555
2024 585
2025 609
2026 363

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,863 results

Results by year

Filters applied: . Clear all
Page 1
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, Cho JM, Kang WC, Yoon HJ, Kim WH, Lee SJ, Lee JB, Jang JY, Shin S, Park IH, Kwon SU, Kim S, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Kim BK; Ez-PAVE Investigators. Lee YJ, et al. Among authors: kim jw. N Engl J Med. 2026 Apr 9;394(14):1365-1375. doi: 10.1056/NEJMoa2600283. Epub 2026 Mar 28. N Engl J Med. 2026. PMID: 41910315 Clinical Trial.
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.
Ryu SY, Deng W, Albuquerque K, Koh WJ, Mayadev J, Heugel A, Kim BJ, Kim DY, Cho CH, Kim JW, No JH, Mannel RS, Miller K, Fabian D, Chase DM, Gil KM, Small W Jr, Rodgers W, Leath CA 3rd, Monk BJ. Ryu SY, et al. Among authors: kim jw. Ann Oncol. 2025 Dec;36(12):1514-1524. doi: 10.1016/j.annonc.2025.09.003. Epub 2025 Sep 12. Ann Oncol. 2025. PMID: 40947016 Free PMC article. Clinical Trial.
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X; ENGOT-ov65/KEYNOTE-B96 investigators. Colombo N, et al. Among authors: kim jw. Lancet. 2026 Apr 18;407(10538):1525-1537. doi: 10.1016/S0140-6736(26)00602-1. Epub 2026 Apr 10. Lancet. 2026. PMID: 41974150 Clinical Trial.
Final Silence.
Kim JW. Kim JW. J Clin Oncol. 2026 Mar;44(7):607-608. doi: 10.1200/JCO-25-01709. Epub 2025 Dec 23. J Clin Oncol. 2026. PMID: 41435209
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
Pant S, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Wasan H, Ducreux M, Bao Y, Wu X, Zhao Y, Garfin PM, Gable J, Harding JJ; HERIZON-BTC-01 Study Group. Pant S, et al. Among authors: kim jw. JAMA Oncol. 2026 Jan 1;12(1):106-109. doi: 10.1001/jamaoncol.2025.4736. JAMA Oncol. 2026. PMID: 41264278 Free PMC article.
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.
Westin SN, Moore K, Chon HS, Pepin JT, Salinas EA, Starks D, Disilvestro PA, Slomovitz B, Vettus E, Gálvez-Montosa F, Agyemang-Prempeh K, Zagouri F, Kim JW, Gao Q, Mejia FC, De Melo AC, Nishikawa T, Kowgier M, Iyer S, Wang Y, Van Nieuwenhuysen E. Westin SN, et al. Among authors: kim jw. Gynecol Oncol. 2026 Mar;206:54-64. doi: 10.1016/j.ygyno.2026.01.777. Epub 2026 Feb 13. Gynecol Oncol. 2026. PMID: 41690202 Free article. Clinical Trial.
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A. Konstantinopoulos PA, et al. Among authors: kim jw. J Clin Oncol. 2025 Sep 10;43(26):2908-2917. doi: 10.1200/JCO-25-00225. Epub 2025 Jul 23. J Clin Oncol. 2025. PMID: 40700681 Free article. Clinical Trial.
9,863 results